Journal of Virology & Antiviral ResearchISSN: 2324-8955

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Favorable Response in A Spanish Cohort of HIV Infected Men with Acute Hepatitis C Infection Who Received Delayed Antiviral Treatment

Favorable Response in A Spanish Cohort of HIV Infected Men with Acute Hepatitis C Infection Who Received Delayed Antiviral Treatment

Background: Early combined therapy within 12 weeks of diagnosis with pegylated interferon (peg-IFN) and ribavirin (RBV) for a period of 24-48 weeks is the recommended treatment for acute hepatitis C (HCV) infection in HIV-infected patients. However, scarce data are available about efficacy of the shorter 24-week regimens in cases of delayed initiation of treatment. We describe here our outcomes among a small cohort of HIV-infected men with acute HCV infection who started treatment significantly beyond 12 weeks of acute HCV diagnosis. Methods: HIV-infected men with acute HCV infection were treated with peg-IFN+RBV using a responseguided therapy algorithm where those achieving rapid virologic response (RVR) received 24 weeks of total therapy and those achieving complete early virologic response (cEVR) received therapy extended 20 weeks beyond their first undetectable HCV viral load (VL). Results: Six HIV-infected men diagnosed with acute HCV infection initiated treatment 16 to 60 weeks after acute HCV infection diagnosis. Three had RVR and were treated for 24 weeks. One with RVR had rebound viremia at week 12 and was treated for 48 weeks. Two without RVR had cEVR and were treated for 28-32 weeks. All 6 men had a sustained virologic response (SVR). Conclusions: Despite significantly delayed initiation of treatment, all of our patients had SVR, most after receiving shorter treatment courses. Shorter courses according to response-guided therapy might therefore be safely recommended for these patients.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations